CDK4 and diffuse large B-cell lymphoma: This integrative computational approach successfully identified mechanistically relevant therapeutic candidates, proteasome inhibitors targeting NF-κB-driven ABC pathogenesis, and CDK4/6 inhibitors addressing the observed CDK4 overexpression, which represent promising starting points for experimental validation and potential combination therapy strategies in ABC DLBCL.